Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in mesenchymal-type resectable colon cancer (window-of-opportunity study)
2014-003965-11Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in colon cancer, sponsored by University Medical Center Utrecht. Primary endpoint: Change in mesenchymal phenotype gene expression. Started Sep 2015; status: active.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2014-003965-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003965-11.